Watches of Switzerland Group shares slid 3.3% to trade at 706p as investor enthusiasm cooled following a high-profile downgrade and a cautious domestic market tone.
Jefferies moved its recommendation on the luxury watch retailer from Buy to Hold, citing the brokerage's view that the recent valuation expansion leaves limited upside after the stock's substantial advance in recent weeks. Despite the downgrade, Jefferies raised its price target to 740p from 440p, a change it said reflects stronger fundamentals beneath the business.
The firm pointed to the stock's valuation at roughly 13.1 times calendar 2027 earnings and observed that this level sits near the upper end of the company's post-COVID valuation band of 7x to 14x. That positioning, Jefferies argued, constrains further upside and underpinned the switch to a less constructive rating.
Jefferies also highlighted the timing of the company's full-year results, scheduled for 14 July, and said it expects those figures to confirm robust underlying demand in North America. The brokerage suggested that such positive signals may already be reflected in the current share price, reducing the potential for the results themselves to act as a fresh catalyst.
Market context offered little assistance to the stock. The wider UK market had slipped in the prior session and trading remained cautious, with ongoing weakness in the pharmaceutical and energy sectors cited as a drag on sentiment. The FTSE 250, of which Watches of Switzerland is a constituent, was modestly lower, providing no meaningful offset to the company-specific headwind.
The downgrade arrived just after a notable rally that saw the shares climb from roughly 625p to close to a 52-week high of 757.5p. That combination - a valuation-driven analyst reassessment and a soft domestic market backdrop - set the scene for the pullback as investors reassessed the near-term risk/reward profile ahead of next week’s results.
Summary
Shares in Watches of Switzerland fell to 706p after Jefferies downgraded the stock to Hold while increasing its price target to 740p; the brokerage cited limited upside because the stock is trading near the top of its post-COVID valuation range and expects upcoming results on 14 July to confirm strong North America demand that may already be priced in.
Key points
- Shares down 3.3% to 706p following a Jefferies downgrade from Buy to Hold.
- Jefferies raised its price target to 740p from 440p but noted limited upside at about 13.1x calendar 2027 earnings versus a 7x-14x post-COVID range.
- Broader UK market softness - including pressure from pharmaceuticals and energy - and a modestly weaker FTSE 250 compounded the stock-specific headwind.
Risks and uncertainties
- Valuation risk - the stock is trading near the upper bound of its stated post-COVID valuation range, leaving limited upside.
- Upcoming earnings risk - full-year results due 14 July may confirm demand trends but, if already priced in, may not provide a fresh positive catalyst.
- Market backdrop risk - continued weakness in key UK sectors and a cautious trading environment could further constrain recovery in the share price.